Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Deals

Novo’s Inversago takeout brings another appetite and glucose modulator to its obesity arsenal

Inversago’s program was geared to revive CB1 receptor as a metabolic target by avoiding the central nervous system

August 11, 2023 12:52 AM UTC

Novo’s acquisition of Canadian biotech Inversago brings the pharma another molecular target with effects on food intake and glucose homeostasis, and is a vote of confidence that peripherally acting agents targeting CB1 receptor won’t have the safety issues of first-generation compounds.

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) announced Thursday it plans to acquire Inversago Pharma Inc. in a deal valued up to $1.1 billion if all development and commercial milestones are met. The deal is expected to close by year-end; details were not disclosed...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article